secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cogent Biosciences, Inc. (COGT)
CIK:        0001622229
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0000950170-22-015744
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cogent Biosciences Q2 net loss $34.9M; cash $325.6M after June public offering
------------------------------------------------------------------------------

- Cash and equivalents $325.6M at June 30, 2022, up from $191M at March 31, 2022; includes $172.6M from June 2022 public offering, funds operations into 2025.
- Net loss $34.9M for Q2 2022 vs $16.5M in Q2 2021; R&D expenses rose to $29.5M from $12.4M on trial costs.
- Positive initial bezuclastinib APEX data: all 11 AdvSM patients achieved ≥50% serum tryptase reduction; no edema, cognitive effects or intracranial bleeding.
- On-track for further APEX data by end of 2022; SUMMIT and PEAK trial data expected in 1H2023.
- Appointed Fang Fang, Ph.D., as VP Biometrics; she brings over 20 years industry experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1622229/000095017022015744/0000950170-22-015744-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1622229/000095017022015744/cogt-20220809.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-015744

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer